---
title: "SGMT.US (SGMT.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SGMT.US/news.md"
symbol: "SGMT.US"
name: "SGMT.US"
parent: "https://longbridge.com/en/quote/SGMT.US.md"
datetime: "2026-03-17T04:16:06.775Z"
locales:
  - [en](https://longbridge.com/en/quote/SGMT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SGMT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SGMT.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/SGMT.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/SGMT.US/news.md)


# SGMT.US (SGMT.US) — Related News

### [Sagimet Biosciences (NASDAQ:SGMT) Upgraded to "Hold" at Wall Street Zen](https://longbridge.com/en/news/279111145.md)
*2026-03-14T05:40:23.000Z*
> Sagimet Biosciences (NASDAQ:SGMT) has been upgraded from a "sell" to a "hold" rating by Wall Street Zen. Other analysts 

### [Sagimet: Undervalued MASH and Acne Pipeline with Best-in-Class Combination Potential Supports Buy Rating](https://longbridge.com/en/news/278746755.md)
*2026-03-11T15:15:33.000Z*
> Sagimet Biosciences, Inc. received a Buy rating from analyst Brandon Folkes of H.C. Wainwright, with a price target of $

### [Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress](https://longbridge.com/en/news/278716419.md)
*2026-03-11T11:59:08.000Z*
> Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress

### [Sagimet Biosciences | 8-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/278714030.md)
*2026-03-11T11:44:51.000Z*
### [Sagimet Biosciences Q4 net loss narrows as R&D expenses fall](https://longbridge.com/en/news/278713236.md)
*2026-03-11T11:39:27.000Z*
### [Sagimet 10-K: Net Loss $51.0M, EPS $(1.58)](https://longbridge.com/en/news/278713423.md)
*2026-03-11T11:35:01.000Z*
> Sagimet reported a net loss of $51.0 million for the year, with an operating loss of $56.9 million, resulting in a net l

### [Sagimet Biosciences | 10-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/278712261.md)
*2026-03-11T11:33:21.000Z*
### [Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf.](https://longbridge.com/en/news/277369696.md)
*2026-03-01T20:38:51.000Z*
> Sagimet Biosciences presented its strategy on fatty acid synthase (FASN) inhibition at Oppenheimer’s Healthcare Conferen

### [Sagimet Biosciences Showcases FASN Strategy, MASH Phase II Timeline and Acne Data at Guggenheim Conference](https://longbridge.com/en/news/275998870.md)
*2026-02-15T08:06:16.000Z*
> Sagimet Biosciences presented its strategy targeting fatty acid synthase (FASN) at the Guggenheim Emerging Outlook Confe

### [Sagimet Biosciences to Present at Guggenheim Emerging Outlook Biotech Summit](https://longbridge.com/en/news/274967332.md)
*2026-02-05T12:00:44.000Z*